Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › lanadelumab

lanadelumab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of lanadelumab

8 trials tracked of lanadelumab: 6 in phase 3 or 4 and 4 with published results. The most-cited published study has 152 citations.

8Trials tracked
6Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 6 Phase 1 2
  1. Phase 3 Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients Completed · 152 cited
  2. Phase 3 A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children Completed · 28 cited
  3. Phase 3 A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor Completed · 4 cited
  4. Phase 3 A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) Completed · 4 cited
  5. Phase 3 Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE) Completed
  6. Phase 3 A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE) Completed
Show 2 more trials
  1. Phase 1 Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects Completed
  2. Phase 1 A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Lanadelumab reduced attacks in Chinese adults with hereditary angioedema over six months
Allergy & Immunology Phase III
Lanadelumab reduced attacks in Chinese adults with hereditary angioedema over six months Imagine waking up with severe swelling in your throat. It feels like you cannot breathe. This is what hereditary angioedema feels like for many people
This open-label study evaluated safety and efficacy of subcutaneous lanadelumab in patients with hereditary angioedema in China.
This rare condition causes painful swelling under the skin.
Frontiers Apr 29, 2026